DHPLC screening of cystic fibrosis gene mutations
暂无分享,去创建一个
[1] P. Oefner,et al. Denaturing high‐performance liquid chromatography: A review , 2001, Human mutation.
[2] C. Férec,et al. Complete and rapid scanning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by denaturing high-performance liquid chromatography (D-HPLC): major implications for genetic counselling , 2001, Human Genetics.
[3] B. Zbar,et al. Random mutagenesis‐PCR to introduce alterations into defined DNA sequences for validation of SNP and mutation detection methods , 2001, Human mutation.
[4] K. Klinger,et al. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening , 2001, Genetics in Medicine.
[5] W. Grody,et al. Cystic fibrosis population carrier screening: Here at last—Are we ready? , 2001, Genetics in Medicine.
[6] R. Cotton,et al. Using CCM and DHPLC to detect mutations in the glucocorticoid receptor in atherosclerosis: a comparison. , 2001, Journal of biochemical and biophysical methods.
[7] H. Zoghbi,et al. Diagnostic testing for Rett syndrome by DHPLC and direct sequencing analysis of the MECP2 gene: identification of several novel mutations and polymorphisms. , 2000, American journal of human genetics.
[8] H. Smeets,et al. Autosomal dominant Alport syndrome caused by a COL4A3 splice site mutation. , 2000, Kidney international.
[9] X. Estivill,et al. Recommendations for quality improvement in genetic testing for cystic fibrosis European Concerted Action on Cystic Fibrosis , 2000, European Journal of Human Genetics.
[10] E. Lau,et al. Prenatal diagnosis of glycogen storage disease type 1b using denaturing high performance liquid chromatography , 2000, Prenatal diagnosis.
[11] R. Santer,et al. Molecular analysis in glycogen storage disease 1 non‐A: DHPLC detection of the highly prevalent exon 8 mutations of the G6PT1 gene in German patients , 2000, Human mutation.
[12] C. Giunta,et al. Characterization of 11 new mutations in COL3A1 of individuals with Ehlers‐Danlos syndrome type IV: Preliminary comparison of RNase cleavage, EMC and DHPLC assays , 2000, Human mutation.
[13] J. Cheadle,et al. Application and evaluation of denaturing HPLC for molecular genetic analysis in tuberous sclerosis , 2000, Human Genetics.
[14] D. Kwiatkowski,et al. Superiority of Denaturing High Performance Liquid Chromatography over single‐stranded conformation and conformation‐sensitive gel electrophoresis for mutation detection in TSC2 , 1999, Annals of human genetics.
[15] M. O’Donovan,et al. Optimal temperature selection for mutation detection by denaturing HPLC and comparison to single-stranded conformation polymorphism and heteroduplex analysis. , 1999, Clinical chemistry.
[16] E. Gross,et al. A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC , 1999, Human Genetics.
[17] M. Mennuti,et al. Screening for cystic fibrosis carrier state. , 1999, Obstetrics and gynecology.
[18] S N Thibodeau,et al. Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations. , 1998, Nucleic acids research.
[19] M. Ferrari,et al. Optimized Detection of DNA Point Mutations by Double Gradient Denaturing Gradient Gel , 1998, Clinical chemistry and laboratory medicine.
[20] R. W. Davis,et al. Detection of numerous Y chromosome biallelic polymorphisms by denaturing high-performance liquid chromatography. , 1997, Genome research.
[21] A. Macková,et al. Identification of common cystic fibrosis mutations in African-Americans with cystic fibrosis increases the detection rate to 75%. , 1997, American journal of human genetics.
[22] Xavier Estivill,et al. Complexity in a monogenic disease , 1996, Nature Genetics.
[23] D. Glavač,et al. Sensitivity of single-strand conformation polymorphism and heteroduplex method for mutation detection in the cystic fibrosis gene. , 1994, Human molecular genetics.
[24] X. Estivill,et al. Analysis of the CFTR gene confirms the high genetic heterogeneity of the Spanish population: 43 mutations account for only 78% of CF chromosomes , 1994, Human Genetics.
[25] A. Ferguson,et al. Three novel mutations in the cystic fibrosis gene detected by chemical cleavage: analysis of variant splicing and a nonsense mutation. , 1992, Human molecular genetics.
[26] L. Tsui,et al. Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. , 1991, Genomics.
[27] L. Tsui,et al. The cystic fibrosis gene: isolation and significance. , 1990, Hospital practice.
[28] E. L. Pettit,et al. Novel method for molecular detection of the two common hereditary hemochromatosis mutations. , 2000, Genetic testing.
[29] J. Wahlström,et al. Denaturing high-performance liquid chromatography is a suitable method for PMM2 mutation screening in carbohydrate-deficient glycoprotein syndrome type IA patients. , 2000, Genetic Testing.
[30] D. Glavač,et al. Screening methods for cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in non-human primates , 2000, Pflügers Archiv.
[31] D. Glavač,et al. Screening methods for cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in non-human primates , 2000, Pflügers Archiv: European Journal of Physiology.
[32] Genetic testing for cystic fibrosis. National Institutes of Health Consensus Development Conference Statement on genetic testing for cystic fibrosis. , 1999, Archives of internal medicine.
[33] X. Estivill,et al. Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations , 1997 .
[34] X. Estivill,et al. Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. The Biomed CF Mutation Analysis Consortium. , 1997, Human mutation.
[35] L. Tsui,et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.